EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Monte Rosa Therapeutics's enterprise value is $102.32 Mil.
Monte Rosa Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $1.06 Mil. Therefore, Monte Rosa Therapeutics's EV-to-Revenue for today is 96.17.
The historical rank and industry rank for Monte Rosa Therapeutics's EV-to-Revenue or its related term are showing as below:
GLUE'
s EV-to-Revenue Range Over the Past 10 Years
Min: 135.38 Med: 180.61 Max: 268.81
Current: 96.17
During the past 5 years, the highest EV-to-Revenue of Monte Rosa Therapeutics was 268.81. The lowest was 135.38. And the median was 180.61.
GLUE's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 7.95
vs GLUE: 96.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Monte Rosa Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Monte Rosa Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monte Rosa Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Monte Rosa Therapeutics's EV-to-Revenue falls into.
Monte Rosa Therapeutics's current Enterprise Value is $102.32 Mil.
Monte Rosa Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monte Rosa Therapeutics (NAS:GLUE) EV-to-Revenue Explanation
Monte Rosa Therapeutics's share price for today is $5.00.
Monte Rosa Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monte Rosa Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Monte Rosa Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Monte Rosa Therapeutics (Monte Rosa Therapeutics) Business Description
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLUE has been successfully added to your 